Alphanuke Medical Technology Co., Ltd. has recently announced the successful conclusion of its A1 funding round, spearheaded by Hebei Coastal Industry Investment Fund and bolstered by contributions from existing shareholders. The infused capital will primarily serve to establish a production hub in Shijiazhuang, North China, and introduce a cutting-edge generation of 30 MeV commercial cyclotrons. The objective is to establish a regional hub for medical isotope supply and radiopharmaceutical production. Established in 2020, Alphanuke specializes in the research and development of alpha-emitting radionuclides and their corresponding labeled drugs. With a robust drug pipeline aimed at various tumor indications and collaborations with numerous tertiary hospitals, the company stands poised for growth. The new production base in North China will work in tandem with the R&D center in Ningbo and the Jiaxing base to bolster nationwide supply capacity and expedite response times. Alphanuke remains steadfast in its commitment to constructing a precision radiotherapy system centered around astatine-211, thereby accelerating the clinical application and transformation of alpha-emitting radiopharmaceuticals.